Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 16, 2019 08:00 ET | Source: RAPT Therapeutics, Inc.

RAPT Therapeutics to be Added to the Russell 2000® and Russell Microcap® Indices

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing...
December 11, 2019 08:00 ET | Source: RAPT Therapeutics, Inc.

RAPT Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing...
December 10, 2019 08:00 ET | Source: RAPT Therapeutics, Inc.

RAPT Therapeutics Appoints Mary Ann Gray, Ph.D., to Board of Directors

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing...
December 04, 2019 08:00 ET | Source: RAPT Therapeutics, Inc.

RAPT Therapeutics Appoints Rodney Young as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing...
December 03, 2019 16:05 ET | Source: RAPT Therapeutics, Inc.

RAPT Therapeutics and Hanmi Pharmaceutical Announce Collaboration to Develop and Commercialize FLX475 in Asia

SOUTH SAN FRANCISCO, Calif. and SEOUL, South Korea, Dec. 03, 2019 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on...
March 31, 2017 15:44 ET | Source: FLX Bio

CORRECTING and REPLACING -- FLX Bio to Present Poster at the American Association of Cancer Research (AACR) Conference on its Lead Immuno-Oncology Program Targeting CCR4

In a release issued under the same headline earlier today by FLX Bio, Inc., please note that the link to the abstract title under the Abstract information section was incorrect and has...
March 31, 2017 11:00 ET | Source: FLX Bio

FLX Bio to Present Poster at the American Association of Cancer Research (AACR) Conference on its Lead Immuno-Oncology Program Targeting CCR4

SOUTH SAN FRANCISCO, Calif., March 31, 2017 (GLOBE NEWSWIRE) -- FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of novel immuno-oncology (IO) agents and...
December 12, 2016 12:42 ET | Source: FLX Bio

FLX Bio, Inc. Appoints Linda Kozick to its Board of Directors

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of novel immuno-oncology agents, announced today...
April 26, 2016 12:00 ET | Source: RAPT Therapeutics, Inc.

FLX Bio Announces $50 Million Series B Financing

SOUTH SAN FRANCISCO, Calif., April 26, 2016 (GLOBE NEWSWIRE) -- FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies, announced a $50...
April 05, 2016 11:00 ET | Source: RAPT Therapeutics, Inc.

FLX Bio Completes Leadership Team in Immuno-Oncology Drug Discovery

SOUTH SAN FRANCISCO, Calif., April 05, 2016 (GLOBE NEWSWIRE) -- FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies, announced today...